Naftopidil versus tamsulosin versus silodosin in Japanese prostate cancer patients with 125I brachytherapy-induced lower urinary tract symptoms

Trial Profile

Naftopidil versus tamsulosin versus silodosin in Japanese prostate cancer patients with 125I brachytherapy-induced lower urinary tract symptoms

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2011

At a glance

  • Drugs Naftopidil (Primary) ; Silodosin (Primary) ; Tamsulosin (Primary)
  • Indications Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2011 Results published in the International Journal of Radiation Oncology, Biology, Physics.
    • 10 Jun 2011 New trial record
    • 19 May 2011 Results presented at the 106th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top